Ex vivo animal or challenge model as method to measure...

Details Ex vivo animal or challenge model as method to measure... Ex vivo animal or challenge model as method to measure...

2007-07-26

2010-06-29

Mondesi, Robert B (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Parasitic organism or component thereof or substance...

C424S184100, C424S191100, C435S069100, C435S069500, C435S069700, C530S300000, C530S350000, C536S023100, C536S023500, C536S023700

Reexamination Certificate

active

07744907

ABSTRACT:
The invention relates to an ex vivo animal or challenge model as a method to identify protective (recombinant) proteins and rapidly measure protective immunity in intestinal segments directed against parasites and vaccines directed against parasitic infections. The invention further relates to vaccines directed against infection with parasites, such asFasciola hepatica, which vaccines contain protective (recombinant) proteins identified and shown to be protective in studies using the ex vivo model. The invention further relates to protective (recombinant) proteins obtained from newly excysted juveniles (NEJ) ofFasciola hepatica. The protective (recombinant) protein corresponding to an NEJ protein has an apparent molecular weight of 32 kD and an N-terminal amino acid sequence comprising the sequence XXDVSWPFWDRMYNY (SEQ ID NO:1).

REFERENCES:
patent: 6551594 (2003-04-01), van Milligen et al.
patent: 2215104 (1996-09-01), None
patent: WO 94/17820 (1994-08-01), None
patent: WO 96/29605 (1996-09-01), None
Lederman et al (Molecular Immunology 28:1171-1181, 1991.
Li et al , Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980.
Lammas et al 1982, pp. 52-56, ( The ELISA: enzyme-linked immunosorbent assay in veterinary research and Diagnosis, Edited by R. C. Wardley, J. R. Crowther, Martinu Nijhoff publishers under The Use of Elisa to Detect Antigen Release From JuvenileFasciola hepatica).
Mulcahy, G., Cathepsin L Proteinases as vaccines against infection withFasciola hepatica(liver fluke) in ruminants, Research in Veterinary Science, 2001, pp. 83-86.
Berasain et al., J. Parasitol, 1997, 83; 1-5.
Bowie et al., Science, vol. 247: 1990; pp. 1306-1310.
Dalton et al., 1996, Infection and Immunity; 60; 5066-5074.
Herbert et al., The Dictionary of Immunology, Academic Press, 3rd Edition, London, 1985, pp. 58-59.
Houghten et al., Vaccines, 1986, edited by Fred Brown: Cold Spring Harbor Laboratory.
Illustrated Dictionary of Immunology 1995, CRC Press, Inc., edited by Julius M. Cruse, p. 21.
Kawano et al., J. Vet. Med. Sci. 1992; 54; 69-73.
Milner et al., 1994, sequence alignment.
Oshima et al., 1993, Journal of Protein chemistry, vol. 12, No. 4, pp. 403-412.
Saz Howard, 1981, Chapter 17, Medical Microbiology and Infectious Diseases, edited by Braude; W.B. Saunders Company, Philadelphia.
Tkalcevic et al., Biochemical and Biophysics Research Communications, 1995, 213; 169-174.
Wijffels et al., Biochem., 299; 781-790.
Cornelissen et al., Early immunodiagnosis of fasciolosis in ruminants using recominantFasciola hepaticacathepsin L-like protease, International Journal of Parasitology, 2001, pp. 728-737, vol. 31.
Cornelissen et al., Use of a pre-selected epitope of cathepsin-L1 in a highly specific peptide-based immunoassay for the diagnosis ofFasciola hepaticainfections in cattle, International Journal of Parasitology, 1999, pp. 685-696, vol. 29.
Gassenbeek et al., An experimental study of triclabendazole resistance ofFasciola hepaticain sheep, Veterinary Parasitology, 2001, pp. 37-43, vol. 95.
Harmsen et al., Identification of a novelFasciola hepaticacathepsin L protease containing protective epitopes within the propeptide, International Journal for Parasitology, 2004, pp. 675-682, vol. 34.
Reszka et al.,Fasciola hepaticaprocathepsin L3 protein expressed by a baculovirus recombinant can partly protect rats against fasciolosis, Vaccine, 2005, pp. 2987-2993, vol. 23.
Van Milligen et al.,Fasciola hepatica: An Antigen Fraction Derived from Newly Excysted Juveniles, Containing an Immunoreactive 32-kDa Protein, Induces Strong Protective Immunity in Rats, Experimental Parasitology, 2000, pp. 163-171, vol. 94.
Van Milligen et al., Location of Induction and Expression of Protective Immunity againstFasciola hepaticaat the Gut Level: A Study Using an Ex Vivo Infection Model with Ligated Gut Segments, J. Parasitol., 1998, pp. 771-777, vol. 84, No. 4.
Van Milligen et al., A novel ex vivo rat infection model to study protective immunity againstFasciola hepaticaat the gut level, Journal of Immunological Methods, 1998, pp. 183-190, vol. 213.
Van Milligen et al., Protection againstFasciola hepaticain the intestine is highly correlated with eosinophil and immunoglobulin G1 responses against newly excysted juveniles, Parasite Immunology, 1999, pp. 243-251, vol. 21.
Van Milligen et al., Protection toFasciola hepaticain the gut mucosa of immune rats is associated with infiltrates of eosinophils, IgG1 and IgG2a antibodies around the parasites, Parasite Immunology, 1998, pp. 285-292, vol. 20.
De Leeuw et al., Abstract, Comparison of three enzyme immunoassays for diagnosis of Dictyocaulus viviparus infection, Vet. Parasitol., Sep. 1993, pp. 229-241, vol. 49, No. 2-4.
Lang et al.; Host-Parasite Relationships ofFasciola hepaticain the White Mouse. VIII. Successful Vaccination with Culture Incubate Antigens and Antigens from Sonic Disruption of Immature Worms, The Journal of Parasitology, Dec. 1977, pp. 1046-1049, vol. 63, No. 6.

Affiliated with

Also associated with

Rating

Ex vivo animal or challenge model as method to measure... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ex vivo animal or challenge model as method to measure..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ex vivo animal or challenge model as method to measure... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4244458